What is alglucosidase alfa?
Alglucosidase alfa (brand name Myozyme) is an enzyme replacement therapy used to treat Pompe disease, a rare inherited disorder caused by acid alpha-glucosidase (GAA) deficiency. The drug provides recombinant GAA to help break down glycogen in the body’s cells. [1]
What is it used for in Pompe disease?
Alglucosidase alfa is indicated for Pompe disease. It is used for patients who have the disease due to deficient GAA activity, including infants and children, depending on the specific regulatory indications in a country. [1]
How is it given?
Alglucosidase alfa is given as an intravenous infusion (through a vein). Treatment is typically lifelong, with dosing and infusion schedules set by the prescribing clinician based on patient factors and regional labeling. [1]
How does it work?
Pompe disease results from a lack of functional acid alpha-glucosidase, which leads to glycogen buildup in lysosomes. Alglucosidase alfa supplies the missing enzyme so cells can degrade glycogen more effectively. [1]
What side effects are patients monitored for?
Because it is a protein therapy given by infusion, people receiving alglucosidase alfa can develop infusion-related reactions and may form antibodies against the drug. Clinicians monitor for hypersensitivity and infusion tolerability during treatment. [1]
Is it the same as other Pompe enzyme replacement therapies?
Alglucosidase alfa is one enzyme replacement option for Pompe disease; other products include other forms of recombinant GAA used in some settings. Choice depends on availability, country approval, patient characteristics, and clinician judgment. [1]
Key practical questions patients ask
Patients commonly ask about infusion scheduling, how long they must continue therapy, monitoring for immune reactions, and how response is measured (such as changes in muscle function and cardiopulmonary outcomes). These decisions depend on disease severity and how patients respond over time. [1]
Sources:
[1] https://www.myozyme.com/ (Myozyme, alglucosidase alfa prescribing information and product information)